3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July

This article is a valuation-focused dividend stock pitch, arguing that large-cap income names are attractive while the S&P 500 continues to climb. It highlights Pfizer, CVS Health, and AT&T as “absurdly cheap” opportunities, citing low forward P/E ratios, strong or improving cash flow, and durable dividend yields. The piece emphasizes Pfizer’s 7.2% yield and improving product-driven growth, CVS’s earnings recovery and raised 2026 guidance, and AT&T’s 5.4% yield plus record internet subscriber additions and shareholder-return plans through 2028. The market takeaway is a rotation argument: investors crowded into AI and momentum may be overlooking defensive, cash-generative stocks with re-rating potential and income appeal. Overall sentiment is constructive on these stocks, though the article acknowledges company-specific risks such as Pfizer’s legacy COVID revenue decline and AT&T’s heavy debt load.